Tisdag 12 November | 14:44:32 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2025-10-23 07:00 Kvartalsrapport 2025-Q3
2025-07-15 07:00 Kvartalsrapport 2025-Q2
2025-05-15 - Årsstämma
2025-04-24 07:00 Kvartalsrapport 2025-Q1
2025-02-06 08:00 Bokslutskommuniké 2024
2024-10-24 - Kvartalsrapport 2024-Q3
2024-07-16 - Kvartalsrapport 2024-Q2
2024-05-15 - X-dag ordinarie utdelning BACTI B 0.00 SEK
2024-05-14 - Årsstämma
2024-04-25 - Kvartalsrapport 2024-Q1
2024-02-08 - Bokslutskommuniké 2023
2023-10-27 - Kvartalsrapport 2023-Q3
2023-07-18 - Kvartalsrapport 2023-Q2
2023-05-08 - X-dag ordinarie utdelning BACTI B 0.00 SEK
2023-05-05 - Årsstämma
2023-04-27 - Kvartalsrapport 2023-Q1
2023-02-09 - Bokslutskommuniké 2022
2022-10-27 - Kvartalsrapport 2022-Q3
2022-07-14 - Kvartalsrapport 2022-Q2
2022-05-02 - X-dag ordinarie utdelning BACTI B 0.00 SEK
2022-04-29 - Årsstämma
2022-04-27 - Kvartalsrapport 2022-Q1
2022-02-10 - Bokslutskommuniké 2021
2021-10-28 - Kvartalsrapport 2021-Q3
2021-07-15 - Kvartalsrapport 2021-Q2
2021-04-29 - X-dag ordinarie utdelning BACTI B 0.00 SEK
2021-04-28 - Årsstämma
2021-04-22 - Kvartalsrapport 2021-Q1
2021-02-04 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-08-13 - Kvartalsrapport 2020-Q2
2020-05-13 - Kvartalsrapport 2020-Q1
2020-04-29 - X-dag ordinarie utdelning BACTI B 0.00 SEK
2020-04-28 - Årsstämma
2020-02-05 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-08-08 - Kvartalsrapport 2019-Q2
2019-05-16 - X-dag ordinarie utdelning BACTI B 0.00 SEK
2019-05-15 - Årsstämma
2019-05-09 - Kvartalsrapport 2019-Q1
2019-02-07 - Bokslutskommuniké 2018
2018-11-06 - Kvartalsrapport 2018-Q3
2018-08-08 - Kvartalsrapport 2018-Q2
2018-05-17 - X-dag ordinarie utdelning BACTI B 0.00 SEK
2018-05-16 - Årsstämma
2018-05-08 - Kvartalsrapport 2018-Q1
2018-02-06 - Bokslutskommuniké 2017
2017-11-09 - Kvartalsrapport 2017-Q3
2017-08-10 - Kvartalsrapport 2017-Q2
2017-05-19 - X-dag ordinarie utdelning BACTI B 0.00 SEK
2017-05-18 - Årsstämma
2017-05-04 - Kvartalsrapport 2017-Q1
2017-02-09 - Bokslutskommuniké 2016
2016-11-10 - Kvartalsrapport 2016-Q3
2016-08-11 - Kvartalsrapport 2016-Q2
2016-05-20 - X-dag ordinarie utdelning BACTI B 0.00 SEK
2016-05-19 - Årsstämma
2016-05-12 - Kvartalsrapport 2016-Q1
2016-02-18 - Bokslutskommuniké 2015
2015-11-12 - Kvartalsrapport 2015-Q3
2015-08-13 - Kvartalsrapport 2015-Q2
2015-05-22 - X-dag ordinarie utdelning BACTI B 0.00 SEK
2015-05-21 - Årsstämma
2015-05-12 - Kvartalsrapport 2015-Q1
2015-02-19 - Bokslutskommuniké 2014
2014-11-14 - Kvartalsrapport 2014-Q3
2014-11-14 - Analytiker möte 2014
2014-08-15 - Kvartalsrapport 2014-Q2

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Bactiguard är ett globalt medicinteknikbolag som förebygger vårdrelaterade infektioner orsakade av medicintekniska produkter. Teknologin baseras på ett ultratunt ädelmetallytskikt som förebygger mikrobiell adhesion och bildande av biofilm. Bactiguard verkar genom licenssamarbeten med MedTech-företag som tillämpar teknologin på sina medicintekniska produkter. Bolaget har även en portfölj med sårvårdsprodukter. Bactiguard har sitt huvudkontor i Stockholm.
2023-10-12 10:33:16

The medical and technology teams at Bactiguard have, together with KTH, Sweden's largest technical university (Division of Micro and Nanosystems), and Karolinska Institute (Department of Clinical Neuroscience), performed a study on the impact of using Bactiguard's noble metal coating to reduce thrombo-inflammatory reactions and acute stent thrombosis. In short, the conclusion of the study is that when adding the Bactiguard's coating to implant materials, the body's reaction to foreign objects is significantly reduced.

Any medical device that is inserted into the blood stream will cause a so called thrombo-inflammatory reaction. This includes activation of the coagulation system, which potentially can result in a thrombosis. A stent is a metal net designed to open a blood vessel that is obstructed. Activation of the coagulation system and build-up of a thrombosis within a stent is a very serious complication that may lead to injury, or even to death.

The unique feature of Bactiguard's noble metal coating is that it reduces microbial adhesion on the surface of a medical device. Other studies have previously suggested that the coating also can reduce the thrombo-inflammatory reaction. This specific study on the impact of using Bactiguard's coating to reduce thrombo-inflammatory reactions and acute stent thrombosis was performed to gather even more clinical data and proof points of the coating's efficacy. For innovation and future application development purposes, two versions of the coating were applied to the stents in the study - Bactiguard's "standard" coating consisting of gold, silver and palladium, and a modified version including neodymium.

The research methods used were both in vivo (in pigs) and in vitro (through blood marker analysis which also included human samples). The pigs underwent implantation of coated and non-coated stents in a blinded fashion, where the interventionist did not know which stents were coated and which were not. The experiment was terminated after two hours, representing the acute phase of the implantation. The stents were placed in the lingual artery with one coated and one uncoated on each side. The volume of the stent was analyzed using CT-scans data and performed by a treatment blinded assessor. The researchers also conducted laboratory tests using both human and pig blood. Note that the study obtained consent from all human participants involved.

The measurements showed that the coated stent group had a notable decrease in blood clot volume compared to the control group. This effect was observed as early as one hour after the stent was implanted and became even more accentuated after two hours. The in vitro data, using both human and pig blood, showed a significant decrease in markers of coagulation and inflammation in the coated group compared to the control group.

Stefan Grass, Chief Medical Officer at Bactiguard, says: "The finding of this study is promising and yet another set of important data supporting the efficacy of Bactiguard's coating. The combination of infection prevention without increased risk of thrombosis is very appealing and unique for a coated intravascular device."

The study was presented at the ISTH 2023 Congress in Montréal late June, a conference for healthcare professionals working in the fields of thrombosis and hemostasis. The study titled "A novel noble metal stent coating reduces in vitro platelet activation and acute in vivo thrombosis formation: a blinded study" is now published in Scientific Reports. https://www.nature.com/articles/s41598-023-44364-4